Figure 3.

Antitumor effect of miR-21-specific miRNase. (A) Retardation of RLS₄₀ growth in vivo after treatment of RLS₄₀ cells with antisense oligonucleotides, control conjugate (luc-POC), or miR-21-miRNase. (B) Tumor volume on day 19 after RLS₄₀ transplantation. Mice were injected with RLS₄₀ cells either without any treatment (w/t) or treated with Lipofectamine (LF), commercial miR-21 inhibitor at concentration 0.1 µM (Inh 0.1, recommended) and 1 µM (Inh 1, in accordance to concentration of miRNase used in the study), control conjugate (luc-POC, 1 µM), hairpin 2′OMe oligonucleotide (2′-OMe, 1 µM), hairpin antisense oligonucleotide (h-ODN, 1 µM) or miR-21-specific miRNase (miR-21-miRNase, 1 µM). Data were statistically analyzed using two-way ANOVA with post hoc Tukey test. Data are presented as mean ± s.e. p-value indicates a statistically reliable difference. (C) Doubling time of RLS₄₀ tumors after treatment with oligonucleotides and conjugates.